AbCellera Biologics Inc.
ABCL | NASDAQ
$12.66
+$0.03 (+0.24%)
At close: Sep 21, 2026, 4:00 PM ET
$12.61
-$0.05 (-0.39%)
Pre-market:
Sep 22, 2026, 6:17 AM ET
Company Profile
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Key Executives
| Name | Position |
|---|---|
| Carl Hansen | Chief Executive Officer, President & Chairperson |
| Andrew Booth | Chief Financial Officer |
| Tryn T. Stimart | Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Privacy Officer |
| Veronique Lecault | Chief Technology Officer & Director |
| Andrew Knowles | Vice President of Operations |
| Caitlin Webster CIPD | Director of Talent Development |
| Marcie Thiessen | Senior Director of Finance & Accounting |
| Martin Hogan | Senior Director of Strategic Finance & IR |
| Murray McCutcheon | Senior Vice President of Partnering |
| Tiffany Chiu | Vice President of Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 24, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 14, 2026 | 4 | Filing |
| Aug 14, 2026 | 4 | Filing |
| Aug 13, 2026 | 8-K | Current Report |
| Aug 13, 2026 | 424B5 | Filing |
| Aug 13, 2026 | 4 | Filing |
| Aug 11, 2026 | 424B5 | Filing |
| Aug 10, 2026 | 8-K | Current Report |
| Aug 07, 2026 | 8-K | Current Report |
AbCellera Biologics Inc.
| Country | Canada |
| IPO Date | Dec 10, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 562 |
| CEO | Carl Hansen |
Stock Details
| Ticker Symbol | ABCL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001703057 |
| CUSIP Number | 00288U106 |
| ISIN Number | CA00288U1066 |
| SIC Code | 2834 |
Recent News
- 5 days ago / businesswire.comAbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
- 28 days ago / benzinga.comWhat'sGoing On With AbCellera Biologics Stock On Tuesday?
- 1 month ago / seekingalpha.comAre Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes
- 1 month ago / businesswire.comAbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
- 1 month ago / benzinga.comWhat's Going on With AbCellera Biologics Stock On Wednesday?
- 1 month ago / businesswire.comAbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- 1 month ago / defenseworld.netInvestors Buy Large Volume of AbCellera Biologics Call Options (NASDAQ:ABCL)
- 1 month ago / seekingalpha.comAbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript
- 1 month ago / benzinga.comAbCellera Biologics Menopause Drug Data Shows 'New Efficacy Benchmark'
- 1 month ago / gurufocus.comAbCellera Stock Jumps 33% on a Positive Menopause Trial
Add to Watchlist
Select watchlists to add or remove ABCL